replicateBE: Average Bioequivalence with Expanding Limits (ABEL)
Performs comparative bioavailability calculations for Average Bioequivalence with
Expanding Limits (ABEL). Implemented are 'Method A' and 'Method B' and the detection of outliers.
If the design allows, assessment of the empiric Type I Error and iteratively adjusting alpha to
control the consumer risk.
Average Bioequivalence - optionally with a tighter (narrow therapeutic index drugs) or wider
acceptance range (Gulf Cooperation Council, South Africa: Cmax) - is implemented as well.
Version: |
1.1.1 |
Depends: |
R (≥ 3.5.0) |
Imports: |
readxl (≥ 1.0.0), PowerTOST (≥ 1.5.3), lmerTest, nlme, pbkrtest, graphics, grDevices |
Suggests: |
knitr, rmarkdown, testthat, devtools |
Published: |
2022-02-12 |
Author: |
Helmut Schütz
[aut, cre],
Michael Tomashevskiy [ctb],
Detlew Labes
[ctb] |
Maintainer: |
Helmut Schütz <helmut.schuetz at bebac.at> |
BugReports: |
https://github.com/Helmut01/replicateBE/issues |
License: |
GPL (≥ 3) |
URL: |
https://github.com/Helmut01/replicateBE |
NeedsCompilation: |
no |
Materials: |
README NEWS |
In views: |
ClinicalTrials |
CRAN checks: |
replicateBE results |
Documentation:
Downloads:
Linking:
Please use the canonical form
https://CRAN.R-project.org/package=replicateBE
to link to this page.